Introduction
Several recent studies have documented endocrine active compounds (EACs) and other contaminants of emerging concern in surface water in Minnesota (Lee and others, 2004; Lee, Schoenfuss, and others, 2008; Lee, Yaeger, and others, 2008) . Additionally, these contaminants have been detected in groundwater in Minnesota (Erickson, 2012; Lee and others, 2004; Tornes and others, 2007) and nationwide (Zogorski and others, 2006; DeSimone and others, 2009) . Understanding the occurrence and distribution of these compounds in groundwater in Minnesota is important for source-water protection efforts and to better understand the connections between land use and water quality. Wastewater treatment systems, including domestic septic systems, are not designed to remove these types of compounds (Herberer, 2002; Ternes and others, 2002) , potentially providing a transport path for these compounds to groundwater. Lee and others (2004) collected samples from 11 monitoring or production wells, which were located in a variety of land-use settings, including sewered residential, commercial/ industrial, residential septic, landfill, and feedlot. Although few groundwater sites were sampled, the detections of pharmaceuticals, antibiotics, disinfectants, personal-care products (such as sunscreen, insect repellant, and fragrances), plasticizers, pesticides, solvents, detergents, flame retardants, and polycyclic aromatic hydrocarbons in the groundwater samples were notable.
The U.S. Geological Survey (USGS), in cooperation with the Minnesota Pollution Control Agency (MPCA), completed a study on the occurrence of pharmaceuticals and other contaminants of emerging concern in shallow groundwater in non-agricultural areas of Minnesota using wells within the MPCA ambient groundwater monitoring network. The compounds analyzed include steroidal hormones, pharmaceuticals, antibiotics, and organic wastewater compounds. As part of this study, the MPCA collected 46 groundwater samples from 45 wells during 2013 (two environmental samples were collected from one of the wells). These samples were analyzed for 110 pharmaceutical compounds, including steroidal hormones, human-use pharmaceutical compounds, human-and animal-use antibiotics, and a broad suite of organic compounds associated with wastewater, by the USGS National Water Quality Laboratory (NWQL) in Denver, Colorado, or the USGS Organic Geochemistry Research Laboratory in Lawrence, Kansas.
The purposes of this report are to describe the study design and methods of sample collection and laboratory analysis for the study on the occurrence of pharmaceuticals and other contaminants of emerging concern, and present quality-assurance and analytical data for 110 pharmaceutical compounds in 46 groundwater samples collected from 45 wells during 2013. The samples analyzed for pharmaceutical compounds included in this report were analyzed by the USGS NWQL using research method 9017 for pharmaceuticals in filtered water.
Study Design
The study was designed to determine the magnitude of concentrations of pharmaceutical compounds and other organic contaminants of emerging concern in shallow groundwater in non-agricultural areas of Minnesota. The MPCA's ambient groundwater monitoring network (hereafter called the network) (Minnesota Pollution Control Agency, 2009) targets wells completed in the sand and gravel aquifers and vulnerable bedrock aquifers, such as the Prairie du Chien-Jordan aquifer, in areas that are sensitive to pollution, as described by the Minnesota Department of Natural Resources and others (Falteisek, 2013 Erickson (2012) and Erickson and others (2014) .
Pharmaceutical compounds analyzed in groundwater samples for this study include compounds typically found in wastewater, including steroidal hormones, pharmaceuticals, antibiotics, and other organic compounds. Methods and analytical results of research method 9017 are included in this report. Analytical results for a subset of samples analyzed at the NWQL using schedule 2080, which analyzes 14 pharmaceutical compounds in common with research method 9017, also are included in this report. Methods for schedule 2080 are described in Furlong and others (2008) . Although analytical methods are different between research method 9017 and schedule 2080, a comparison of analytical results from the two analytical methods provides information regarding precision and capabilities of research method 9017.
The 45 sampled wells ( fig. 1 ; table 1) are located primarily in non-agricultural areas in proximity to human alterations, such as housing developments or industrial activities. Water samples were collected during the months April through June 2013. Samples were sent to the USGS NWQL in Denver, Colorado, or the USGS Organic Geochemistry Research Laboratory in Lawrence, Kansas, for analysis. Analytical results for hormones, antibiotics, and wastewater compounds in samples analyzed by the NWQL or Organic Geochemistry Research Laboratory using approved methods (Furlong and others, 2008; Meyer and others, 2007; Zaugg and others, 2006) , are published in the USGS National Water Information System (NWIS) (U.S. Geological Survey, 2014), and are not included in this report. These analytical results for hormones, antibiotics, and wastewater compounds can be obtained from NWIS using the station numbers given in table 1.
Methods
This section of the report describes the methods used to collect the groundwater samples and the analytical methods for the analysis of 110 pharmaceutical compounds. Qualityassurance and quality-control samples collected for this study also are described. USGS staff verified sample integrity and labeling, shipped all samples to the USGS laboratories, and entered necessary site and sample information into USGS databases.
Groundwater Sample Collection
Each monitoring well was purged using a submersible or peristaltic pump and Teflon ® tubing. Field properties, such as water temperature, pH, and specific conductance, were measured and recorded in PCFF as specified in the NFM. Samples for analysis by research method 9017 were collected using USGS protocols for organic contaminants (section 5.6.1.F of Wilde and others, 2004) , except that the samples were contained in new 125-milliliter amber glass bottles. Samples for analysis by research method 9017 and all other analyses were filtered in the field using the procedure summarized in Wilde and others (2004) . Samples were stored at 4 degrees Celsius (ºC) or less, until analysis. Sampling equipment was decontaminated between sampling sites using, in sequence, Liqui-Nox ® , tap water, deionized water, methanol, and organic-free blank water. Sampling personnel refrained from using personal-care products (for example, mosquito repellant containing N,N-diethyl-meta-toluamide [DEET]) and participating in activities which may introduce compounds of interest (for example, smoking or drinking coffee) to avoid contamination of the samples during collection.
Analytical Methods for Pharmaceutical Compounds
Groundwater samples were analyzed for 110 pharmaceutical compounds using research method 9017, which was under method research development at the USGS NWQL in 2013. Because this USGS research method was under development, long-term quality-assurance information was not available during the time of this study. The method was approved in 2014 as NWQL schedule 2440, and is briefly described in this section and in more detail in Furlong and others (2014) . A 100-microliter aliquot of the filtered water sample is directly injected into a high-performance liquid chromatograph (HPLC) coupled to a triple quadrupole mass spectrometer using an electrospray ionization source operated in the positive ion mode. Separation of the pharmaceutical compounds is completed using a reversed-phase gradient of formic acid/ammonium formate-modified water and methanol. When possible, a specific isotope dilution standard (IDS) pharmaceutical with chemical similarity to an unlabeled pharmaceutical of interest is added to the sample prior to analysis (table 2). Each pharmaceutical compound is then identified using multiple reaction-monitoring (MRM) of two fragmentations of the protonated molecular ion of each pharmaceutical to two unique product ions. The primary MRM precursor-product ion transition is quantified for each pharmaceutical relative to that of a specific IDS pharmaceutical. This direct injection analysis method results in method detection limits ranging from 0.45 to 94.1 nanograms per liter (ng/L) for the analyzed compounds. An assessment of method performance for each pharmaceutical was conducted to determine the applicability of the method in different matrices. Recovery of a suite of pharmaceuticals spiked into reagent, surface, and drinking water; groundwater; and wastewater influent and treated effluent typically was greater than 90 percent (Furlong and others, 2014) . Table 2 . Pharmaceutical compound and corresponding isotope dilution standard used for its quantification in filtered water samples by U.S. Geological Survey National Water Quality research method 9017. Because research method 9017 is an "information-rich" method, as are other mass spectrometry methods the NWQL provides (Childress and others, 1999) , qualitatively identified compounds for which calculated concentrations are less than the interim reporting level or less than the lowest calibration standard are reported by NWQL as estimated and noted with the "E" remark code. Compounds that are not detected are reported as less than the interim reporting level.
Quality Assurance and Control
Quality-assurance plans were established to evaluate laboratory and field sampling techniques, assess possible sources of contamination, and assure representative samples. All field personnel were familiar with study design and sampling protocols before field sampling or data processing to assure sample integrity.
Field quality-assurance samples were collected consistent with the USGS NFM (U.S. Geological Survey, variously dated). The collected field quality-assurance samples included replicates and blanks (table 3) . Field equipment-blank samples were collected at 4 of the 45 wells to characterize any contamination potentially introduced during field activities. Field replicates were collected at three wells during the 2013 sampling.
Analytical results of the field quality-assurance samples are presented in table 4 as a Microsoft Excel spreadsheet (http:// pubs.usgs.gov/ds/2014/878/downloads/table4.xls).
Potential contamination of water samples during sample collection, processing, and laboratory analysis was assessed with field equipment-blank samples. Field equipment-blank samples were prepared at selected sites before a scheduled field sample. Field equipment-blank samples were prepared by processing HPLC organic-free grade water (certified by the USGS to be free of the compounds of interest) through the same equipment used to collect and process field samples. Four field blank samples were collected and analyzed to assess contamination introduced during sample collection and processing and laboratory analysis for water samples. At least one compound was detected in three of the four field equipmentblank samples. Nine compounds were detected among all field blank samples (table 4). Seven compounds were detected in one of the field equipment-blank samples, the most detections in any one field blank. Three (one-third) of the compounds detected in field equipment-blank samples were detected in two of the blank samples (1,7-dimethylxanthine, caffeine, and lidocaine); six (two-thirds) of the compounds detected in field equipment-blank samples were detected in one blank sample. Piperonyl butoxide and pseudoephedrine were each detected in one field equipment-blank sample, but were not detected in environmental samples. Several compounds detected in field equipment-blank samples were also detected in environmental samples. However, compounds detected in field blank samples did not correspond to associated environmental samples collected on the same day. Despite the lack of association between field blank and environmental sample detections, environmental sample concentrations that were less than 10 times any field equipment-blank concentration were assigned a 'v' code in table 4 and are not counted as detections in this report. Future interpretation of these data warrants consideration of the compound detections in field equipment-blank samples.
Replicate samples are used to quantify the variability of detections and corresponding concentrations that result from sample processing (sample splitting, filtration, and transport) and laboratory techniques. Three replicate samples were collected at three different wells. Replicate sample pairs consisted of a primary environmental field sample and a replicate sample collected immediately after the environmental sample; the two samples should be nearly identical in composition. Concentrations of detected compounds in replicate samples were compared by calculating the relative standard deviation (RSD) for each detected compound. The RSD is calculated by dividing the standard deviation of the samples by the mean of the samples, and then multiplying by 100. None of the three sequential replicate sample pairs that were collected had detections of the same compounds and therefore, it was not possible to calculate RSD for those samples. No compounds were detected in the environmental or replicate sample collected from site 42 ( fig. 1; table 4 ). One compound (caffeine) was detected in the replicate sample collected from site 14 (fig. 1) ; however, that compound was not detected in the associated environmental sample. The concentration of caffeine in the replicate samples was less than 10 times the concentration detected in a field equipment-blank sample, so the value was assigned a 'v' code in table 4. Compound detections in paired samples collected from site 8 ( fig. 1 ; table 4) also were not consistent between the samples. Two compounds, acetaminophen and metaxalone, were detected in the environmental sample, but not in the replicate sample. The concentration of acetaminophen was less than 10 times the concentration detected in a field equipment-blank sample, so the value was assigned a 'v' code in table 4. The concentration of metaxalone in the environmental sample was reported as an estimated (E) value because it was less than the interim reporting level.
Five samples were analyzed for pharmaceutical compounds using schedule 2080 and research method 9017. Analytical results from the two methods allowed for comparison between the old (schedule 2080) and new (research method 9017) analytical methods for pharmaceutical compounds.
Laboratory quality-control samples were used to validate and interpret the environmental data. Laboratory qualitycontrol samples included laboratory reagent blanks, reagent spikes, matrix spikes, and surrogates. At least one fortified laboratory reagent spike sample and one laboratory reagent blank sample were analyzed with each set of 10-16 environmental samples. Laboratory reagent blanks are samples of reagent water that are assumed to be void of the compounds of interest. Laboratory reagent blank samples were used to assess potential sample contamination. Several pharmaceutical compounds were detected in the laboratory reagent blank samples at concentrations greater than the interim reporting level. At least one pharmaceutical compound was detected in every laboratory reagent blank sample. Two of the 13 laboratory reagent blank samples included in analyses had detections of 15 pharmaceutical compounds, which was the greatest number of detections in laboratory blanks. Fexofenidine was the most frequently detected compound in laboratory reagent blank samples, detected in all but one laboratory reagent blank sample. Chlorpheniramine was detected in more than one-half of all laboratory reagent blank samples. Despite detections in laboratory reagent blanks, neither fexofenadine nor chlorpheniramine were detected in any environmental samples. Warfarin was the only compound detected in both an environmental sample and associated laboratory reagent blank; the environmental sample concentration was E13.9 ng/L (table 4), which was less than 10 times the laboratory reagent blank concentration, so it was assigned a 'v' code and not counted as a detection in this report (U.S. Geological Survey, 2011).
Recoveries for compounds spiked into reagent water (laboratory reagent spike samples) and for surrogate compounds spiked into environmental samples indicate the general proficiency of the laboratory methods. Laboratory reagent spikes are samples of reagent water that are spiked (fortified) in the laboratory with a known concentration of selected compounds. Average recoveries of compounds in laboratory reagent spike samples ranged from 77 percent (cimetidine) to 112 percent (pseudoephedrine). For research method 9017, surrogate compounds were added to samples before analysis to monitor method performance, as described in the "Analytical Methods for Pharmaceutical Compounds" section. Surrogates are chemicals that have similar properties to the analytes of interest, but do not interfere with quantitation of the compounds of interest. Average recovery of surrogate compounds in environmental samples ranged from 81 percent (pseudoephedrine-d 3 ) to 112 percent (hydrocodone-d 3 ). Recovery of compounds and surrogates were within acceptable ranges of 50-150 percent (Furlong and others, 2014) indicating general good recovery of pharmaceutical compounds using this analytical method.
Matrix interference was to be assessed by laboratory matrix spikes in groundwater samples. Two matrix spike samples with associated duplicate samples were collected at two wells and shipped to the NWQL for assessment of matrix interference. In cases when the environmental sample concentration was less than the method detection limit, a concentration of zero was used to estimate percent recovery of the spiked analyte. Recoveries of target analytes spiked into sample matrices ranged from 26 to 471 percent, indicating the sample matrix may have interfered with recovery of some analytes. Orlistat had the overall lowest recovery, ranging from 26 to 76 percent. Recoveries of two compounds, lamivudine and penciclovir, were greater than 200 percent in all spiked samples, indicating that environmental concentrations may be biased high. Compound recoveries generally were consistent between duplicate matrix spike samples.
Pharmaceutical Compounds in Groundwater
The concentration data for the 110 pharmaceutical compounds in 46 groundwater samples collected from 45 wells in Minnesota during 2013 are presented in table 4, along with the associated percent recoveries for IDS pharmaceuticals. Environmental samples from 21 wells had detectable concentrations of at least one of the 110 pharmaceutical compounds analyzed using USGS NWQL research method 9017 (table 4, Microsoft® Excel spreadsheet; figs. 2 and 3). Fewer than 5 compounds were detected in most samples. One sample contained detectable concentrations of nine compounds (site 25, fig. 1 ; table 4), which was the most compounds detected in one sample. Twenty-seven of the 110 compounds analyzed were detected in at least one groundwater sample. Twelve of the 27 detected compounds were detected in more than one sample and are shown in figure 3 . The remaining 15 of 27 detected compounds were detected in only one groundwater sample. Most detected compounds were detected in fewer than four samples. Desmethyldiltiazem and nicotine were the most frequently detected compounds (detected in 5 of 46 environmental samples). Detectable concentrations of all compounds ranged from 0.43 to 2,060 ng/L, with caffeine having the highest detectable concentration.
One well (site 24) was sampled twice approximately one month apart in 2013. Although this set of samples is not being considered as a replicate pair, they provide important information regarding temporal variation in the groundwater chemistry and how representative a one-time sampling of these wells may be. The two samples collected at site 24 (station number 452153093133501, site 24, fig. 1 ) on May 20 and June 25 contained detectable concentrations of carisoprodol and meprobamate with RSDs of 59 and 14, respectively.
Five samples were analyzed with both USGS NWQL research method 9017 and schedule 2080. Schedule 2080 analyzes the presence of 14 pharmaceuticals in samples using solid-phase extraction and liquid chromatography-mass spectrometry methods (Furlong and others, 2008) . Percent recovery of surrogates generally was greater using research method 9017 compared to schedule 2080, although different surrogates were used between the two methods. Average recoveries for the two surrogates used in schedule 2080 were 51 and 70 percent for carbamazepine-d 10 and ethylnicotinated 4 , respectively. Research method 9017 includes analysis of 19 surrogates (IDS pharmaceuticals) for which average recoveries ranged from 81 to 112 percent. Table 5 shows a comparison of results between the two pharmaceutical methods, research method 9017 and laboratory schedule 2080. Laboratory reporting limits used for schedule 2080 are up to 10-fold higher compared to interim reporting limits used for research method 9017. Three pharmaceuticals were detected with schedule 2080. Sulfamethoxazole was detected in two samples, and acetaminophen and carbamazepine were detected in one sample. Five pharmaceuticals were detected when samples were analyzed with research method 9017, although three of those detections were associated with detections in laboratory equipment-blank samples and were coded with a 'v' in tables 4 and 5. Two detections were in common between schedule 2080 and research method 9017: carbamazepine and sulfamethoxazole (in one of two paired samples with a detection using schedule 2080). 
Summary
The U.S. Geological Survey, in cooperation with the Minnesota Pollution Control Agency, completed a study on the occurrence of pharmaceutical compounds and other contaminants of emerging concern in shallow groundwater in non-agricultural areas of Minnesota during 2013. This report describes the study design and methods for the study on the occurrence of pharmaceuticals and other contaminants of emerging concern, and presents the data collected on pharmaceutical compounds. A total of 46 environmental samples and 11 quality-control samples were collected from 45 wells as part of this study. Samples were analyzed by the U.S. Geological Survey National Water Quality Laboratory for 110 pharmaceutical compounds using research method 9017. Environmental samples from 21 wells had detectable concentrations of one or more pharmaceutical compounds. One sample contained detectable concentrations of nine compounds, which was the most detected in one sample. Fewer than 5 compounds were detected in most samples. Among all samples, 27 of 110 pharmaceutical compounds were detected in at least one sample. Detectable concentrations of all compounds ranged from 0.43 to 2,060 nanograms per liter, with caffeine having the highest detectable concentration. Desmethyldiltiazem and nicotine were the most frequently detected compounds (detected in 5 of 46 environmental samples).
